(Q43816273)

27 November 2017

Correlation between reduction in plasma HIV-1 RNA concentration 1 week after start of antiretroviral treatment and longer-term efficacy (English)

1 reference

27 November 2017

1

1 reference

27 November 2017

2

1 reference

27 November 2017

C Yoder

3

1 reference

27 November 2017

S Jankelevich

4

1 reference

27 November 2017

J Metcalf

5

1 reference

27 November 2017

B U Mueller

6

1 reference

27 November 2017

M A Dimitrov

7

1 reference

27 November 2017

P Pizzo

8

1 reference

27 November 2017

R Yarchoan

9

1 reference

27 November 2017

D S Dimitrov

10

1 reference

27 November 2017

language of work or name

English

0 references

publication date

1 November 2001

1 reference

27 November 2017

1 reference

27 November 2017

358

1 reference

27 November 2017

1760-1765

1 reference

27 November 2017

9295

1 reference

Prognosis in HIV-1 infection predicted by the quantity of virus in plasma

27 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906802-7

7 January 2021

The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906802-7

7 January 2021

Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906802-7

7 January 2021

Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. VA Cooperative Study Group on AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906802-7

7 January 2021

Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906802-7

7 January 2021

Predictors of optimal virological response to potent antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906802-7

7 January 2021

The virological response to highly active antiretroviral therapy over the first 24 weeks of therapy according to the pre-therapy viral load and the weeks 4–8 viral load

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906802-7

7 January 2021

Patterns of plasma human immunodeficiency virus type 1 RNA response to antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906802-7

7 January 2021

Individual prognoses of long-term responses to antiretroviral treatment based on virological, immunological and pharmacological parameters measured during the first week under therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906802-7

7 January 2021

Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationships to host factors, cellular restoration, and virologic end points

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906802-7

7 January 2021

Short-term measures of relative efficacy predict longer-term reductions in human immunodeficiency virus type 1 RNA levels following nelfinavir monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906802-7

7 January 2021

A phase I/II study of the protease inhibitor indinavir in children with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906802-7

7 January 2021

A phase I/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906802-7

7 January 2021

Decay characteristics of HIV-1-infected compartments during combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906802-7

7 January 2021

Ongoing HIV dissemination during HAART.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906802-7

7 January 2021

Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906802-7

7 January 2021

Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906802-7

7 January 2021

The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906802-7

7 January 2021

Mathematical analysis of antiretroviral therapy aimed at HIV-1 eradication or maintenance of low viral loads

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906802-7

7 January 2021

HIV infection: how effective is drug combination treatment?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906802-7

7 January 2021

Why are the decay rates in plasma HIV-1 different for different treatments and in different patient populations?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906802-7

7 January 2021

A model of HIV-1 pathogenesis that includes an intracellular delay.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906802-7

7 January 2021

10.1016/S0140-6736(01)06802-7

Identifiers

DOI

1 reference

27 November 2017

1 reference